In January of 2022, Osmind announced the publication of the largest real-world analysis of ketamine infusion therapy for depression. The results were impressive.
How effective is ketamine infusion therapy?
In a subset of 537 patients receiving ketamine infusion therapy (KIT) across 178 clinics, there was a 54% response rate and 30% remission rate (in this case, remission is defined as a lessening in symptoms of depression).
Further, about 40% of patients with suicidal ideation no longer experienced it after their infusion therapy. Over 70% of patients reported experiencing a general improvement in suicidal ideation overall. Antidepressant response to KIT was durable to the point that 80% of patients retained this relief at 4 weeks, and 60% at 8 weeks, even without smaller maintenance infusions.
Osmind is a healthcare technology company and Public Benefit Corporation (PBC), and published the results of the study in the Journal of Affective Disorders. The study was conducted with leading physician-scientists at Stanford University School of Medicine, and is the largest-ever published analysis of Ketamine Infusion Therapy (KIT) outcomes in community care settings.
“Ketamine infusion therapy is the future of mental healthcare in this country,” said Dr. Aubrey Verdun, MD and Medical Director at Freedom Ketamine Treatment Centers.
Large, real-world evidence studies like this one are crucial in advocating for insurance coverage of and patient access to these treatments.
In the meantime, infusion therapy is available at select clinics across the U.S. One highly-rated option in the DMV is Freedom Ketamine Treatment Centers, with offices in Rockville, Bethesda, Columbia, Reston, Vienna, and Marshall.
To schedule a consultation with this practice, visit freedomketaminecenters.com, or call (301) 235-9022.
Comments